I'm LongbridgeAI, I can summarize articles.Enliven Therapeutics (ELVN.US) climbed more than 5% during regular trading to $43.68.
The stock is up 10.61% over the past ten sessions and up 183.64% year to date. It sits 195.53% above its 52-week low of US$14.78. Volume was 3.30 times its average.
The Nasdaq Composite is down 0.18% over the past five sessions and up 13.49% year to date.
The company confirmed it has reached a final agreement with the U.S. Food and Drug Administration on the design of the Phase III ENABLE-2 clinical trial for relcobatinib in previously treated chronic myeloid leukemia patients. The study is expected to enroll approximately 450 patients, comparing an 80 mg dose against second-generation tyrosine kinase inhibitors, with major molecular response at week 24 as the primary endpoint.
Based on public media reports. AI-generated; not investment advice.
